Human Breast Cancer (ER+/PR+/Her2-), FFPE Sections

Human ER+PR+HER2- Breast Cancer is a specific subtype of breast cancer characterized by the presence of two hormone receptors—Estrogen Receptor (ER) and Progesterone Receptor (PR)—while lacking expression of the Human Epidermal Growth Factor Receptor 2 (HER2). In this subtype, cancer cells in the breast tissue have receptors for estrogen and progesterone but do not exhibit overexpression of HER2.

The presence of ER and PR receptors indicates that the cancer cells are responsive to hormones like estrogen and progesterone. Understanding this receptor status is crucial for guiding treatment decisions. Hormone therapy, which targets the hormonal receptors, is often a key component of the treatment plan for Triple Positive ER+PR+HER2+ Breast Cancer.

The absence of HER2 overexpression distinguishes this subtype from other Triple Positive breast cancer subtypes. The identification of the specific molecular characteristics of the cancer helps in developing tailored and effective treatment strategies for individuals diagnosed with Triple Positive ER+PR+HER2+ Breast Cancer.

VitroVivo Provide high quality ER+PR+HER2- Breast Cancer FFPE sections to assist your breast cancer research. These FFPE sections are mounted on positively charged glass slides and sectioned at 5 µm thickness. These FFPE slides can be used to perform RNA scope ISH, FISH IF, IHC and NGS, etc.